Enzyme-Linked Immunosorbent Assay Testing Market Report 2026

The enzyme-linked immunosorbent assay testing market size has grown strongly in recent years. It will grow from $3.04 billion in 2025 to $3.24 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to widespread use of elisa in diagnostic testing, expansion of biomedical research activities, increasing prevalence of infectious and chronic diseases, growing reliance on immunoassays, availability of standardized testing protocols.

The enzyme-linked immunosorbent assay testing market size is expected to see strong growth in the next few years. It will grow to $4.12 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to increasing adoption of automated laboratory workflows, rising demand for biomarker-based diagnostics, expansion of elisa applications in oncology and immunology, growing focus on early disease detection, increasing investment in clinical research infrastructure. Major trends in the forecast period include increasing adoption of high-throughput elisa platforms, rising demand for multiplex immunoassays, growing integration of automated sample processing, expansion of elisa use in clinical research, enhanced focus on assay sensitivity and accuracy.

The rising incidence of infectious disorders is expected to drive the growth of the enzyme-linked immunosorbent assay (ELISA) testing market in the coming years. Infectious disorders are caused by pathogenic microorganisms, including bacteria, viruses, fungi, and parasites, which can spread between individuals and affect multiple body systems. Factors such as increased global travel and the rise of antimicrobial resistance contribute to the growing prevalence of these infections, complicating infection control efforts. ELISA testing supports infectious disorder management by enabling accurate detection and quantification of specific antigens or antibodies associated with infections, aiding in diagnosis, monitoring disease progression, and evaluating treatment efficacy. For example, in February 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental public health organization, 58,114 measles cases - a highly contagious viral disease - were reported in the European Region in 2023, compared to 941 cases in 2022. Consequently, the increasing incidence of infectious disorders is driving the ELISA testing market.

Leading companies in the ELISA testing market are focusing on product innovations, such as novel ELISA kits, to improve diagnostic accuracy and support quality control in research and clinical applications. Novel ELISA kits are advanced versions of traditional tests that provide enhanced accuracy, sensitivity, and usability for detecting and quantifying biomarkers. For instance, in February 2023, Charles River Laboratories, a US-based pharmaceutical company, launched a novel ELISA kit designed to detect and quantify residual host cell proteins (HCP) in CHO-based biotherapeutics. This kit uses avian immunoglobulin Y (IgY) antibodies sourced from specific pathogen-free (SPF) chicken eggs, offering high sensitivity and specificity with detection limits as low as 0.1 ng/mL and 90% antibody coverage. The launch aims to improve quality control in biopharmaceutical development, ensuring safety and efficacy while allowing flexible use by clients, either independently or with support from Charles River's experts.

In February 2024, Dyadic International Inc., a US-based biotechnology company, partnered with Cygnus Technologies to provide a C1 HCP ELISA, enhancing quality assurance in biomanufacturing. This collaboration focuses on quantifying host cell proteins (HCPs) derived from Dyadic's proprietary C1 cells, which are based on the filamentous fungus *Thermothelomyces heterothallica*. Cygnus Technologies LLC is a US-based biopharmaceutical company specializing in immunoassay solutions.

Major companies operating in the enzyme-linked immunosorbent assay testing market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Siemens Healthineers, Becton Dickinson and Company, Agilent Technologies Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Tecan Group Ltd., GenScript Biotech Corporation, Promega Corporation, Abcam plc, R&D Systems Inc, Sino Biological Inc., OriGene Technologies Inc., RayBiotech Inc., Santa Cruz Biotechnology Inc., AnaSpec Inc., Biomatik, Arigo Biolaboratories Corp., MyBioSource Inc., Boster Biological Technology, Eagle Biosciences Inc., Enzo Life Sciences Inc., StressMarq Biosciences Inc., XpressBio.

North America was the largest region in the enzyme-linked immunosorbent assay testing market in 2025. The regions covered in the enzyme-linked immunosorbent assay testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the enzyme-linked immunosorbent assay testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the elisa testing market by increasing costs of imported antibodies, enzymes, microplates, detection reagents, and automated analyzers used in diagnostic and research laboratories. Hospitals and research facilities in North America and Europe are most affected due to reliance on imported assay components, while Asia-Pacific faces cost pressures in scaling laboratory testing capacity. These tariffs are increasing per-test costs and procurement challenges. However, they are also encouraging local reagent manufacturing, regional production of assay kits, and innovation in cost-effective elisa testing solutions.

The enzyme-linked immunosorbent assay testing market research report is one of a series of new reports that provides enzyme-linked immunosorbent assay testing market statistics, including enzyme-linked immunosorbent assay testing industry global market size, regional shares, competitors with a enzyme-linked immunosorbent assay testing market share, detailed enzyme-linked immunosorbent assay testing market segments, market trends and opportunities, and any further data you may need to thrive in the enzyme-linked immunosorbent assay testing industry. This enzyme-linked immunosorbent assay testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Enzyme-linked immunosorbent assay (ELISA) testing is a widely used laboratory technique for detecting and quantifying specific proteins, antigens, or antibodies in a sample. The method involves immobilizing an antigen or antibody on a solid surface, usually a microplate, and then using enzyme-linked antibodies or antigens to bind the target molecule.

The main types of ELISA testing include direct ELISA, sandwich ELISA, indirect ELISA, multiple and portable ELISAs, and competitive ELISA. Direct ELISA involves immobilizing an antigen directly on a solid surface. ELISA testing is applied in areas such as immunology, inflammation, infectious diseases, cancer, protein quantitation, and more. It serves a variety of end users, including hospitals and diagnostic centers, research laboratories, and other healthcare and scientific institutions.

The enzyme-linked immunosorbent assay testing market consists of revenues earned by entities providing services such as diagnostic testing, research and development, detection of antibodies, and vaccine development. The market value includes the value of related goods sold by the service provider or included within the service offering. The enzyme-linked immunosorbent assay testing market also includes sales of ELISA kits, control samples, inhibitor assays, and other consumables such as microplate readers, washers, and automated ELISA systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.